Top U.S. Genetic Testing Companies

Skyquest Technology's expert advisors have carried out comprehensive research and identified these companies as industry leaders in the U.S. Genetic Testing Market. This Analysis is based on comprehensive primary and secondary research on the corporate strategies, financial and operational performance, product portfolio, market share and brand analysis of all the leading U.S. Genetic Testing industry players.

U.S. Genetic Testing Market Competitive Landscape

The landscape reflects the presence of both established and up-and-coming players in the competitive setting. The two businesses Myriad Genetics and Quest Diagnostics that were the market leader. Due to its extensive genetic testing, Quest Diagnostics dominates the market portfolio with a variety of application areas, including autoimmune disorders, different disorders, as well as heart problems. Due to its existence, Myriad Genetics is anticipated to be the second largest firm in terms of market revenue share in technologically sophisticated goods. Some of Myriad's well-known product lines, EndoPredict and MyRisk are examples of genetics. In other businesses like BioReference, Ambry Genetics, and Invitae Corporation, the goal of laboratories is to keep their position supported by innovative product offerings. Strong investment activities are expected to support R&D endeavors to lead to the emergence of new players

Top Players in the Global US Genetic Testing Market

  • 23andMe
  • AncestryDNA
  • Invitae Corporation
  • Quest Diagnostics
  • Myriad Genetics
  • Illumina, Inc.
  • GeneDx
  • Ambry Genetics
  • BGI Group
  • Blueprint Genetics
  • Counsyl, Inc.
  • Natera, Inc.
  • Roche Diagnostics
  • Genomic Health
  • Guardant Health
  • Helix OpCo LLC
  • Opko Health
  • Thermo Fisher Scientific
  • Veracyte
  • Fulgent Genetics

US Genetic Testing Market Recent Development

  • April 2021 – Invitae Corporation announced that their sponsored genetic testing is available for patients at risk of developing some common adult neurodegenerative conditions in the region of US, Canada, Australia, and Brazil. This availability of this program will be free of cost and will help at-risk individuals having difficulty diagnosing conditions
  • April 2021 – Invitae Corporation announced that they will join the eMERGE network, a national effort organized and funded by National Genome Research Institute. As a part of this partnership, Invitae will provide genetic testing for all 25,000 patients.
  • March 2021 – GI OnDemand announced a partnership with Ambry Genetics to integrate the online genetic counseling and testing services into their nationwide gastroenterology practices. The partnership was made to identify hereditary GI cancer syndromes to guide through potentially life-altering healthcare decisions.
REPORT OVERVIEW BUY NOW

REQUEST FOR SAMPLE

Want to customize this report? REQUEST FREE CUSTOMIZATION

FAQs

U.S. Genetic Testing Market size was valued at USD 6.03 Billion in 2024 and is poised to grow from USD 6.49 Billion in 2025 to USD 11.76 Billion by 2033, growing at a CAGR of 7.7% during the forecast period (2026–2033). 

The landscape reflects the presence of both established and up-and-coming players in the competitive setting. The two businesses Myriad Genetics and Quest Diagnostics that were the market leader. Due to its extensive genetic testing, Quest Diagnostics dominates the market portfolio with a variety of application areas, including autoimmune disorders, different disorders, as well as heart problems. Due to its existence, Myriad Genetics is anticipated to be the second largest firm in terms of market revenue share in technologically sophisticated goods. Some of Myriad's well-known product lines, EndoPredict and MyRisk are examples of genetics. In other businesses like BioReference, Ambry Genetics, and Invitae Corporation, the goal of laboratories is to keep their position supported by innovative product offerings. Strong investment activities are expected to support R&D endeavors to lead to the emergence of new players 'Natera (United States) ', 'Myriad Genetics (United States) ', 'Guardant Health (United States) ', '23andMe (United States) ', 'Color Genomics (United States) ', 'Fulgent Genetics (United States) ', 'GeneDx (United States) ', 'Pathway Genomics (United States) ', 'Progenity (United States) ', 'Sema4 (United States) ', 'Veracyte (United States) ', 'BioReference Laboratories (United States) ', 'Quest Diagnostics (United States) ', 'Labcorp (United States) ', 'Genomic Health (United States) '

Growing need for early and preventive care is one of the key factors influencing the growth of the U.S. genetic testing industry. Healthcare providers and governmental organizations are placing a larger emphasis on early detection and screening for health hazards as a result of the rising cost of treating diseases. The Centers for Disease Control and Prevention (CDC) estimate that the direct and indirect expenses of treating chronic illnesses like cardiovascular disease in the American healthcare system total USD 320 billion yearly.

The considerable and steady increase in insurance coverage of genetic tests for various types by major insurance companies is one of the most important trends in the U.S. genetic testing business. Many insurance providers are expanding their coverage to evaluate the effectiveness of mental medications. Psychiatric medications are notoriously difficult to fit the patient's symptoms. Due to this, many people who are now utilizing psychiatric medications use a trial-and-error system in an effort to find the best remedy for them successfully. For Instance, UnitedHealthcare, the biggest insurer in the United States, started extending insurance coverage beginning on October 1, 2019, for anyone aged over 27 plans, both private and public.

In terms of geography, North America led the global genetic testing market in terms of revenue in 2019 and is anticipated to continue to lead the market during the forecast period. This is explained by the majority of important actors being present in the region. However, due to increased affordability, a rise in healthcare spending, and increased awareness of early genetic condition screening, Asia-Pacific is anticipated to expand at the highest CAGR throughout the projection period.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Genetic Testing Market
Buy Now GET FREE SAMPLE
Direct-to-Consumer Genetic Testing Market
Buy Now GET FREE SAMPLE
Genetic Toxicology Testing Market
Buy Now GET FREE SAMPLE
Fertility Test Market
Buy Now GET FREE SAMPLE
Fertility Testing Devices Market
Buy Now GET FREE SAMPLE
Sterility Testing Market
Buy Now GET FREE SAMPLE
Biological Safety Testing Market
Buy Now GET FREE SAMPLE
DNA Forensics Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

US genetic testing market
U.S. Genetic Testing Market

Report ID: SQMIC35A2876

sales@skyquestt.com
USA +1 351-333-4748

BUY NOW GET FREE SAMPLE